A Unique Approach to in vivo CAR T Therapy and New Advancements in the Field

In this episode, Vera spoke with Tim Culp, PhD, Vice President of Research and Development at Interius BioTherapeutics, a Philadelphia-based biotech company.

Their lead program focuses on an intravenous CAR therapy for B cell lymphomas. Additionally, the company is advancing a second program aimed at treating autoimmune diseases.

Dr. Culp joined Interius following a distinguished 14-year career with Merck Research Laboratories where he supported vaccine and oncolytic virus program development as a Senior Principal Scientist. His experience includes leadership of both early and late-stage development teams responsible for all Chemistry, Manufacturing and Controls (CMC) deliverables needed for clinical programs.

Dr. Culp completed a PhD from the Pennsylvania State University, College of Medicine for his research on human papillomaviruses. He then completed post-doctoral studies at Penn State developing chimeric papillomavirus vaccines. Dr. Culp holds a BS in Biology/Secondary Education from Christian Heritage College and had a 15-year high school teaching career prior to his graduate studies.

Tune into the episode to learn more about the promise of in vivo CAR T therapy and novel advancements in the field.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Follow Us on Social Media
Twitter:   / xtalks  
Instagram:   / xtalks  
Facebook:   / xtalks.webinars  
LinkedIn:   / xtalks-webconferences  
YouTube:    / xtalkswebinars